Here are the 10-Q quarterly reports from Obsidian Therapeutics, Inc. (OBX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OBX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OBX filings page.
Obsidian Therapeutics, Inc. is a Delaware-based, clinical-stage biopharmaceutical company developing engineered tumor infiltrating lymphocyte cell therapies for solid tumors. A corporate reorganization created Gazelle Parent, Inc. on April 10, 2026, which later completed merger transactions with Obsidian and Galera Therapeutics, Inc. under an Agreement and Plan of Merger effective August 3, 2026.
In connection with these mergers, qualified institutional and accredited investors agreed to a $350.0 million Concurrent PIPE Financing in Legacy Galera Series C Non-Voting Convertible Preferred Stock, alongside a registration rights agreement for resale of resulting common shares. Legacy Galera stockholders also received contingent value rights tied to 80% of potential future net proceeds from a Legacy Product for five years and 95% from a Supportive-Care Product divestiture for ten years. As of August 10, 2026, Obsidian had 61,772,876 shares of common stock outstanding, and management reported effective disclosure controls with no material changes in internal control over financial reporting.